[Therapeutic cytapheresis].
In myeloproliferative disorders many complications are caused by circulatory problems due to high leukocyte or platelet numbers and by hyperviscosity. With cytaphereses and mild cytostatics like Azathioprine, these problems are solved quickly and without major side effects. We report about plateletaphereses for polycythemia vera and megacaryocytic myelosis and leukocytaphereses for chronic myelogenous leukemia. In addition, erythrocytaphereses were carried out successfully in a patient with a combination of heterozygous sickle cell anemia and thalassemia minor.
Wiebecke
D
D
Abteilung für Transfusionsmedizin und Immunhämatologie, Universität Würzburg.
Gunzer
U
U
Ullrich
H
H
Kadar
J
J
D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000628:therapy; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000295:instrumentation*; D002469:Cell Separation / Q000295:instrumentation*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood / Q000628:therapy*; D011087:Polycythemia Vera / Q000097:blood / Q000628:therapy; D013789:Thalassemia / Q000097:blood / Q000628:therapy
Therapeutische Zytapheresen.